Dosage forms and related therapies

• US 9,993,443 B2
• Filed: 07/22/2016
• Issued: 06/12/2018
• Est. Priority Date: 08/20/2002
• Status: Expired due to Fees

• Current Assignee: Philera New Zealand Limited
• Original Assignee: Philera New Zealand Limited
• Inventors: Cooper, Garth James Smith
• Primary Examiner(s): PACKARD, BENJAMIN J
• Application Number:
  US15/096,570
• Publication Number:
  US 20160324804A1
• Time in Patent Office: 690 Days
• CPC Class Codes: A61K 31/131 acyclic
• CPC Class Codes: A61K 31/132 having two or more amino groups, e.g. spermidine, putrescine
• CPC Class Codes: A61K 31/194 having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• CPC Class Codes: A61K 31/30 Copper compounds
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 39/04 Chelating agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/06 Antiarrhythmics
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogs, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.

Claims

1. A method of treatment for the prevention or amelioration of tissue damage in a subject who does not have Wilson'"'"'s disease to prevent or ameliorate tissue damage, the method comprising administering to said subject a therapeutically effective amount of a succinic acid addition salt of triethylenetetramine, wherein the tissue damage is associated with,

(a) diabetic cardiomyopathy, diabetic acute coronary syndrome, diabetic hypertensive cardiomyopathy, acute coronary syndrome associated with impaired glucose tolerance, acute coronary syndrome associated with impaired fasting glucose, hypertensive cardiomyopathy associated with impaired glucose tolerance, hypertensive cardiomyopathy associated with impaired fasting glucose, ischemic cardiomyopathy associated with impaired glucose tolerance, or ischemic cardiomyopathy associated with impaired fasting glucose;

(b) myocardial infarction, ischemic cardiomyopathy associated with coronary heart disease, cardiomyopathy, myocarditis, idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, acute coronary syndrome not associated with any abnormality of glucose metabolism, hypertensive cardiomyopathy not associated with any abnormality of glucose metabolism, or ischemic cardiomyopathy not associated with any abnormality of glucose metabolism;

or

(c) disease states of an artery selected from aorta, carotid, cerebrovascular, coronary, renal, retinal, iliac, femoral, popliteal, vasa nervorum, arteriolar tree, and capillary bed, and atheromatous disorders of the major blood vessels selected from the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, or the popliteal arteries.

2. The method of claim 1 wherein said succinic acid addition salt of triethylenetetramine is administered to said subject for treatment of a disease, condition or disorder selected from the group consisting of diabetic cardiomyopathy, diabetic acute coronary syndrome, diabetic hypertensive cardiomyopathy, acute coronary syndrome associated with impaired glucose tolerance, acute coronary syndrome associated with impaired fasting glucose, hypertensive cardiomyopathy associated with impaired glucose tolerance, hypertensive cardiomyopathy associated with impaired fasting glucose, ischemic cardiomyopathy associated with impaired glucose tolerance, and ischemic cardiomyopathy associated with impaired fasting glucose.

3. The method of claim 1 wherein said succinic acid addition salt of triethylenetetramine is administered to said subject for treatment of a disease, condition or disorder selected from the group consisting of myocardial infarction, ischemic cardiomyopathy associated with coronary heart disease, cardiomyopathy, myocarditis, idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, acute coronary syndrome not associated with any abnormality of glucose metabolism, hypertensive cardiomyopathy not associated with any abnormality of glucose metabolism, and ischemic cardiomyopathy not associated with any abnormality of glucose metabolism.

4. The method of claim 1 wherein said succinic acid addition salt of triethylenetetramine is administered to said subject for treatment of a disease, condition or disorder of arteries selected from the group consisting of aorta, carotid, cerebrovascular, coronary, renal, retinal, iliac, femoral, popliteal, vasa nervorum, arteriolar tree and capillary bed, and atheromatous disorders of the major blood vessels selected from the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries.

5. The method of claim 1 wherein said succinic acid addition salt of triethylenetetramine is administered to said subject for treatment of cardiac structure damage.

6. The method of claim 5 wherein said cardiac structure damage is selected from the group consisting of atrophy, loss of myocytes, expansion of the extracellular space, and increased deposition of extracellular matrix.

7. The method of claim 1 wherein said succinic acid addition salt of triethylenetetramine is administered to said subject for treatment of coronary artery structure damage.

8. The method of claim 7 wherein said coronary artery structure damage is selected from the group consisting of media layer damage and intima layer damage.

9. The method of claim 1 wherein said succinic acid addition salt of triethylenetetramine is administered to said subject for treatment of plaque rupture of atheromatous lesions of one or more major blood vessels.

10. The method of claim 9 wherein said major blood vessels are selected from the group consisting of the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries and the popliteal arteries.

11. The method of claim 1 wherein said succinic acid addition salt of triethylenetetramine is administered to said subject for treatment of a disease, condition or disorder selected from the group consisting of systolic dysfunction, diastolic dysfunction, aberrant contractility, aberrant recoil characteristics, and aberrant ejection fraction.

12. The method of claim 1 wherein said succinic acid addition salt of triethylenetetramine is administered to said subject for treatment of a disease, condition or disorder comprising microvascular disease.

13. The method of claim 12 wherein said microvascular disease comprises a disorder of one or more of vessels selected from the group consisting of retinal arterioles, glomerular arterioles, vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, the central nervous system, and the peripheral nervous system.

14. The method of claim 1 wherein said succinic acid addition salt of triethylenetetramine is administered in a single dose or in divided doses.

15. The method of claim 1 wherein about 5 mg to about 1100 mg of said succinic acid addition salt of triethylenetetramine is administered per day in a single dose or in divided doses.

16. The method of claim 1 wherein said succinic acid addition salt of triethylenetetramine is a trientine prodrug.

17. The method of claim 1 wherein said administration is parenteral.

18. The method of claim 17 wherein said parenteral administration is by a route selected from the group consisting of transdermal delivery, topical application, suppository delivery, transmucosal delivery, inhalation, insufflation, buccal delivery, sublingual delivery, and ophthalmic delivery.

19. The method of claim 17 wherein said administration is by injection.

20. The method of claim 19 wherein said injection is by subcutaneous injection, subdermal injection, intramuscular injection, depot administration, or intravenous injection.